Isotechnika receives USAN approval for generic name for lead immunosuppressive drug

    EDMONTON, March 12 /CNW/ - Isotechnika Inc. announced today that the
Company has received approval from United States Adopted Name (USAN) for
naming of its lead immunosuppressive drug, ISA247.
    The name, voclosporin, is now being reviewed by the International
Nonproprietary Name (INN) expert committee. The INN is scheduled to publish
the proposed list of approved names sometime in mid 2007. Official
notification from the INN would allow Isotechnika to use the name voclosporin
in labelling, publications, and on drug information. The name will serve to
identify the active pharmaceutical substance during the drugs' life-time
    ISA247 (voclosporin) is a calcineurin inhibitor, currently being
investigated in a Phase 3 European/Canadian trial for the treatment of
moderate to severe psoriasis and a Phase 2b North American trial for the
prevention of organ rejection in kidney transplant patients and as a treatment
for uveitis in three separate pivotal Phase 2/Phase 3 trials. The latter trial
is being coordinated by our partner, Lux Biosciences.
    "Moving toward the name of voclosporin from the previous nomenclature of
ISA247 should assist us in initiating our commercial branding process. The
next step in the naming process is to request that the USAN approved name,
voclosporin, be approved by the International Nonproprietary Name (INN)
Programme of the World Health Organization (WHO). Pending receipt of this INN
approval, ISA247 will, in all future materials, be referred to by its new
generic name, voclosporin," commented Dr. Randall Yatscoff, Isotechnika's
President & CEO.

    About Isotechnika

    Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in
medicinal chemistry and immunology, the Company is focused on the discovery
and development of novel immunosuppressive therapeutics that are safer than
currently available treatments. Its entrepreneurial management and world-class
team of scientists are building a pipeline of immunosuppressive drug
candidates for treatment of autoimmune diseases and for use in the prevention
of organ rejection in transplantation. Isotechnika looks to become the leader
in development of immunosuppressant therapies.
    Isotechnika's lead compound, ISA247 has successfully completed a Phase 3
Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is
currently being investigated in a combined Phase 3 European/Canadian psoriasis
trial and a Phase 2b North American trial for the prevention of kidney graft
rejection. The Company also has an additional immunosuppressive compound in
its drug pipeline, TAFA93 which successfully completed Phase 1 clinical
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found

    Partnerships with Isotechnika Inc.

    Isotechnika Inc. signed a collaboration agreement with Hoffman La Roche
on April 9, 2002, which licensed the worldwide rights to develop and
commercialize voclosporine for all transplant indications.
    On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the use of
voclosporine and TAFA93 specifically with drug eluting devices for the
non-systemic treatment of vascular, cardiovascular, target vessel and tissue
    Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an exclusive license
to develop and commercialize conjugates consisting of Cellgate's patented
transporter technology for the topical delivery of voclosporine in patients
suffering from mild to moderate psoriasis.
    On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead drug,
voclosporine for the treatment and prophylaxis of all ophthalmic diseases.

    Forward-Looking Statements

    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

    %SEDAR: 00010508E

For further information:

For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., (780) 487-1600 (246), (780) 484-4105 (fax),; Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., (780) 487-1600 (243), (780) 487-4105 (fax),

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890